Skip to content
Beacon

BIBProShares Ultra Nasdaq Biotechnology

Take a bet16y track recordRanked #311 of 949 in this goal

Seeks daily investment results that correspond to 2x the daily performance of the Nasdaq Biotechnology Index.

By ProShares · Launched 2010

Annual Cost

0.95%

#4,876 of 5,854 · expensive

Fund Size

$84M

#3,159 of 5,854 · mid-size

Return (1Y)Goal

+89.2%

Track Record

16 years

#753 of 5,854 · established

Performance

Total-return NAV · USD
Growth of $10,000
$15,259+52.6%

Total-return NAV, USD. Net of fund fees, before tax.

What's inside

How Beacon categorizes this fund

Asset class

Equity

Region

North america

Strategy

Leveraged

Sector

Health care

Index tracked

Nasdaq Biotechnology Index

What it actually holds

By weight

Concentration

synthetic exposure — holdings shown are derivatives collateral, not the fund's positions

Gilead Sciences, Inc.
6.5%
N/A
6.3%
Vertex Pharmaceuticals, Inc.
6.3%
Amgen, Inc.
6.2%
Regeneron Pharmaceuticals, Inc.
4.1%
N/A
3.6%
N/A
2.9%
N/A
2.9%
N/A
2.6%
Alnylam Pharmaceuticals, Inc.
2.2%

Asset allocation

Stocks
81.3%
Cash
15.3%
Other
3.5%

By sector

Healthcare
100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years
Volatility (1Y)
40.6%High

Year-on-year price swings

Max drawdown
-66.2%Severe

Worst peak-to-trough loss

Sharpe (3Y)
0.65Decent risk-adjusted returns
Sortino (3Y)
0.93Moderate downside risk

Listing

Exchange
NASDAQ Global Select Market

Full fund details

Objective
Seeks daily investment results that correspond to 2x the daily performance of the Nasdaq Biotechnology Index.
Strategy
Invests in financial instruments to achieve daily returns consistent with the Daily Target, targeting 2x exposure to U.S. and non-U.S. biotechnology and pharmaceutical companies based on market capitalization. Uses derivatives like swap agreements for leveraged exposure and rebalances daily to maintain target exposure.
Inception date
April 6, 2010
Fund family
ProShares

Our take

Structural notes on how this fund behaves. Read our guide on the 6 warning signs.

Leveraged
Warning

Your return drifts the longer you hold

Leverage amplifies the index's daily move, by 2x or 3x. The fund resets every day, so over weeks and months your real return drifts from that multiple. It can run ahead in a smooth climb and bleed in a choppy one. Hold one for months and you own a different bet than the label suggests.

Sources: Cheng & Madhavan, 'The Dynamics of Leveraged and Inverse ETFs' (2009)

Educational analysis of structural product characteristics. Not investment advice. Always read the fund prospectus and consult a qualified advisor before investing. More

What's next?

You've looked at BIB. Save it to your watchlist to weigh it against other funds, then turn your shortlist into a portfolio.

See other funds for this goal

Data updated on 2026-08-04